Partnership to jointly improve tissue assessment in wounds with the use of Near Infrared Imaging technology using Kent’s KD203 device.
| CALGARY, June 27, 2018 /PRNewswire/ - Kent Imaging Inc. and SerenaGroup® today announced a Strategic Partnership to jointly improve tissue assessment in wounds with the use of Near Infrared Imaging technology using Kent’s KD203 device. Oxygenation is widely accepted as the best biomarker of tissue health and healing. Kent’s device is intended for use by healthcare professionals as a non-invasive tissue oxygenation measurement system that reports oxygen saturation (StO2), relative oxyhemoglobin level (HbO2), and relative deoxyhemoglobin (Hb) level in superficial tissue. Kent’s multispectral imaging technology displays two-dimensional color-coded images providing critical information to help clinicians determine at risk tissue and guide treatments to optimize patient outcomes in wound care, plastic surgery, and various other reconstructive applications. This is a great partnership between one of the leaders in building wound care teams and an innovative tissue assessment technology that is easy to use, convenient, and cost effective. SerenaGroup® will adopt Kent Imaging’s technology as the standard of care for assessing wound oxygenation thus wound health. Kent will be integrated into each of the SerenaGroup® managed facilities, included in Hyperbaric training courses curriculum, as well as included in future clinical and preclinical research. “We are pleased to introduce Kent’s imaging system into the wound care protocol at our clinics. One of the most troublesome and elusive criteria in treating wounds is the timely and accurate assessment of viable tissue.” said Dr. Serena MD FACS FACHM MAPWCA, Founder and Medical Director of The SerenaGroup®. “Kent’s device will propel us a long way down the healing path with a technology that has been lacking across the board in the Wound Care space. “ “Our joint belief is that we can improve patient care and outcomes by significantly improving clinically relevant data that is required to assess and manage wounds.” added Pierre Lemire, CEO of Kent Imaging. “We are excited to be partnering with SerenaGroup and with Dr. Serena who has dedicated his career to improving patient outcomes in wound care.” Features of Kent’s Tissue Oxygenation Assessment device:
Kent is available for sale in the United States, Canada, and Europe with FDA Class II clearance, Health Canada clearance, and CE Mark. About Kent Imaging Inc. About SerenaGroup, Inc. View original content with multimedia:http://www.prnewswire.com/news-releases/kent-imaging-inc-and-serenagroup-announce-strategic-partnership-in-wound-care-300672822.html SOURCE Kent Imaging |
